<DOC>
	<DOCNO>NCT00892541</DOCNO>
	<brief_summary>The purpose study evaluate effect organic cation transporter inhibitor , trimethoprim , pharmacokinetics orally administer ER OROS paliperidone ass safety tolerability treatment healthy male volunteer .</brief_summary>
	<brief_title>A Study Potential Effects Trimethoprim Pharmacokinetics ER OROS Paliperidone</brief_title>
	<detailed_description>This study design single center , open-label , randomize , 2 treatment period crossover study healthy male volunteer . The study consist screen period ( within 21 day first study drug administration ) randomization ; open-label treatment phase consist 2 period subject receive single oral dose ER OROS paliperidone alone ( Treatment A ) combination 200 mg trimethoprim twice daily ( Treatment B ) ; end-of-study evaluation upon completion study procedure Period 2 early withdrawal . The pharmacokinetic blood urine sample collect 96 hour period ER OROS paliperidone administration . Successive ER OROS paliperidone administration separate least 14 day . Given main elimination route paliperidone renal clearance half active secretion renal tubule , competition route elimination occur actively secrete drug coadministered . Therefore , possible influence renal excretion paliperidone investigate competitor active renal secretion , trimethoprim , coadministered . Safety tolerability monitor throughout study . Treatment A : single oral dose 6 mg ER OROS paliperidone Day 1 ; Treatment B : 200 mg trimethoprim tablet twice daily Day 1 Day 8 single oral dose 6 mg ER OROS paliperidone Day 5 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Male , age 18 55 year , inclusive Volunteers must sign informed consent document indicate understand purpose procedure require study willing participate study Body Mass Index ( BMI , weight [ kg ] /height [ m² ] ) range 18 28 kg/m² , inclusive Normotensive supine ( 5 minute ) blood pressure range 100 140 mmHg systolic , inclusive , 60 90 mmHg diastolic , inclusive Healthy basis prestudy physical examination , medical history , ECG , laboratory result serum chemistry , hematology urinalysis perform within 21 day first dose . If result serum chemistry , hematology urinalysis test within laboratory 's reference range subject include investigator judge deviation clinically significant Creatinine clearance value great equal 80 mL/min Signed informed consent genetic testing , indicate whether volunteer wish participate genetic part study . Drug allergy risperidone , paliperidone , trimethoprim , excipients history hypersensitivity heparin , case heparin lock use Past current history folic acid deficiency megaloblastic anemia Recent history alcohol substance abuse dependence positive test result urine drug screen screen Relevant history presence cardiovascular ( include myocardial infarct cardiac arrhythmia ) , respiratory , neurological ( include seizure , cerebrovascular disorder ) , psychiatric , renal , hepatic , gastrointestinal ( include surgery , severe gastrointestinal narrowing , malabsorption problem ) , endocrinal , hematological immunological disease . History cancer , exception basal cell carcinoma At screening , decrease &gt; 20 mmHg systolic blood pressure decrease &gt; 10 mmHg diastolic blood pressure stand least 2 minute associated increase &gt; 15 beat per minute ( bpm ) heart rate Bradycardia ( heart rate &lt; 45 bpm ) determine screen ECG A positive result test hepatitis B , C , human immunodeficiency virus ( HIV ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mood disorder</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Renal secretion</keyword>
	<keyword>ER OROS paliperidone</keyword>
</DOC>